Flucofuron as a Promising Therapeutic Agent against Brain-Eating Amoeba

Area of Science:

• Neuroparasitology
• Drug Discovery
• Medicinal Chemistry

Background:

• Primary amoebic meningoencephalitis (PAM) is a rare, severe, and often fatal infection of the brain.
• Caused by the amoeba Naegleria fowleri, PAM lacks standardized therapeutic protocols.
• There is an urgent need for effective treatments against N. fowleri.

Purpose of the Study:

• To identify potential therapeutic agents for PAM from a known compound library.
• To evaluate the efficacy of identified compounds against Naegleria fowleri.
• To explore the mechanism of action of promising drug candidates.

Main Methods:

• Screening of the Medicines for Malaria Venture (MMV) Global Health Priority Box (240 compounds).
• In vitro testing of compound efficacy against Naegleria fowleri trophozoites and cysts.
• Determination of inhibitory concentrations (IC50) for active compounds.
• Analysis of metabolic events induced by the lead compound to infer cell death pathways.

Main Results:

• Flucofuron demonstrated significant efficacy against Naegleria fowleri trophozoites (IC50 values between 2.47-2.58 μM).
• Flucofuron was also effective against the resistant cyst stage (IC50: 0.88 μM).
• Metabolic profiling suggested flucofuron induces apoptosis in N. fowleri.

Conclusions:

• Flucofuron is a promising drug candidate for treating primary amoebic meningoencephalitis.
• Drug repurposing offers a viable strategy for developing treatments for neglected diseases like PAM.
• Further investigation into flucofuron's efficacy and safety is warranted.